https://charts.traderzeitung.de/phases/US22407B1089
string(1372) "{"isin":"US22407B1089","name":"Coya Therapeutics Inc","stock_id":29670147,"generated_at":"2026-10-11 02:26:00","days":[{"date":"2026-10-07","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.92,"close_at":"2026-10-07 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-10-08","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.89,"close_at":"2026-10-08 20:18:00","complete":true,"perf_pct":-0.6098},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-10-09","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.888,"close_at":"2026-10-09 21:22:00","complete":true,"perf_pct":-0.0409},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Coya Therapeutics Aktie News & Nachrichten
Trading-Room

Coya Therapeutics Aktie News & Nachrichten

[WKN: A3DZRY | Symbol: COYA]
Realtimekurs
   
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Coya Therapeutics

Kursziele: flatexDEGIRO SE, CMC Markets PLC, Scout24 AG, BridgeBio Pharma Inc. und Coya Therapeutics Inc.

flatexDEGIRO SE [DE000FTG1111]: Berenberg bestätigt "Buy" und hebt das Ziel von 45 auf 48 Euro (46...

Coya Therapeutics: Treg-Therapie COYA 302 nimmt Kurs auf ALS-Zulassung und 2,2 Mrd. USD Umsatzpotenzial

Aktuelle Meilensteine und Unternehmensentwicklungen Coya Therapeutics (COYA) hat im Jahr 2026 bedeutende...

  • ‹
  • 1
  • ›
Coya Therapeutics Nachrichtenticker öffnen
MT Newswires 08.06.2026 15:23 Uhr

Coya Therapeutics meldet, dass Phase-2-ALS-Studie in verblindete Verlängerungsphase eintritt

09:22 AM EDT, 06/08/2026 (MT Newswires) -- Coya Therapeutics (COYA) gab am Montag bekannt, dass es die verblindete Verlängerungsphase seiner klinische

MT Newswires 05.06.2026 13:29 Uhr

Roth Capital nimmt die Coverage auf Coya Therapeutics mit einer Kaufempfehlung und einem Kursziel von 12 $ auf

07:28 AM EDT, 06/05/2026 (MT Newswires) -- Coya Therapeutics (COYA) hat laut Analysten, die von FactSet befragt wurden, eine durchschnittliche Kaufemp